Progressive multiple sclerosis exhibits decreasing glutamate and glutamine over two years.
Mult Scler
; 22(1): 112-6, 2016 Jan.
Article
en En
| MEDLINE
| ID: mdl-26014604
ABSTRACT
BACKGROUND:
Few biomarkers of progressive multiple sclerosis (MS) are sensitive to change within the two-year time frame of a clinical trial.OBJECTIVE:
To identify biomarkers of MS disease progression with magnetic resonance spectroscopy (MRS) in secondary progressive MS (SPMS).METHODS:
Forty-seven SPMS subjects were scanned at baseline and annually for two years. Concentrations of N-acetylaspartate, total creatine, total choline, myo-inositol, glutamate, glutamine, and the sum glutamate+glutamine were measured in a single white matter voxel.RESULTS:
Glutamate and glutamine were the only metabolites to show an effect with time with annual declines of (95% confidence interval) glutamate -4.2% (-6.2% to -2.2%, p < 10(-4)), glutamine -7.3% (-11.8% to -2.9%, p = 0.003), and glutamate+glutamine -5.2% (-7.6% to -2.8%, p < 10(-4)). Metabolite rates of change were more apparent than changes in clinical scores or brain atrophy measures.CONCLUSIONS:
The high rates of change of both glutamate and glutamine over two years suggest they are promising new biomarkers of MS disease progression.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Ácido Glutámico
/
Progresión de la Enfermedad
/
Esclerosis Múltiple Crónica Progresiva
/
Glutamina
Tipo de estudio:
Observational_studies
/
Prognostic_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Mult Scler
Asunto de la revista:
NEUROLOGIA
Año:
2016
Tipo del documento:
Article
País de afiliación:
Canadá